Strategies towards Improving the Pharmacokinetic Profile of ε-Substituted Lysinol-Derived HIV Protease Inhibitors

✍ Scribed by Dr. Hemaka A. Rajapakse; Dr. Abbas M. Walji; Keith P. Moore; Hong Zhu; Aurpon W. Mitra; Alison R. Gregro; Elizabeth Tinney; Christine Burlein; Sinoeun Touch; Brenda L. Paton; Dr. Steven S. Carroll; Dr. Daniel J. DiStefano; Dr. Ming-Tain Lai; Dr. Jay A. Grobler; Dr. Rosa I. Sanchez; Dr. Theresa M. Williams; Dr. Joseph P. Vacca; Dr. Philippe G. Nantermet

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 273 KB
• Volume: 6
• Category: Article
• ISSN: 1860-7179
• DOI: 10.1002/cmdc.201000395

✦ Synopsis

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/cmdc.201000395. Scheme 1. a) HCl, MeOH; b) Et 3 N, 4-CO 2 MePhSO 2 Cl, CH 2 Cl 2 ; c) DEAD, Ph 3 P, iso-amyl alcohol, THF; d) LiBH 4 , THF; e) TBDPS-Cl, imidazole, CH 2 Cl 2 ; f) H 2 , Pd(OH) 2 , MeOH; g) NMO, CH 2 Cl 2 , TPAP; h) MgSO 4 , PPTS, tert-butane sulfinamide, CH 2 Cl 2 ; i) R 2 MgX, CH 2 Cl 2 or TMS-CF 3 , TBAT, THF, 0 8C; j) HCl, MeOH; k) EDC, HOAt, (S)-N-(methoxycarbonyl)-b-phenyl-l-phenylalanine. Reaction temperatures and times varied for specific compounds; see the Experimental Section for details.